The human tumor tissue is implanted in the same nude mouse organ from which it came. This type of implant, called orthotopic, can reproduce the histological, genetic and epigenetic human tumors and the patterns of tumor spread, which is not achieved with other methods of implementation. Furthermore, these tumor models will be keys to the development of the so-called personalized medicine against various cancers. Besides ovarian tumors, researchers are experienced in orthotopic implantation of other tumors such as colon, pancreas, breast, endometrial or testicle, and liver metastases and neurofibromatosis. Researchers are currently developing models of lung, head and neck tumors.
The technique has shown the effectiveness of lurbinectedin (PM01183), a drug recently approved by the Food and Drug Administration (FDA) as "orphan drug" against ovarian cancer. This disease is the fifth leading cause of death among women. The survival rate is very low because it is often diagnosed at an advanced stage and appear resistances to chemotherapy with cisplatin. So, it is necessary to find alternative treatments.
The lurbinectedin is a marine-derived drug developed by the pharmaceutical company Pharmamar, from the Zeltia group, which has been shown effective against ovarian tumors resistant to cisplatin in several studies. One of the most compelling studies in preclinical level is the work published now in Clinical Cancer Research. The article confirms that orthotopic implants in laboratory mice are useful not only to deepen the knowledge of tumors, but also to collaborate with the pharmaceutical industry in the process of developing new drugs to treat cancer. Lurbinectedin has recently demonstrated its efficacy in a Phase II study in treatment-resistant ovarian cancer.
The coordinator of the study and researcher at the IDIBELL and ICO, Alberto Villanueva, highlights the importance of the models developed in his laboratory that "allow obtaining tumors grown in mice that reproduce the immunohistochemical, genetic and epigenetic properties of the human tumors and its response to chemotherapy with cisplatin, that is the base of the treatment against ovarian cancer."
Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer. Vidal A, Munoz C, Guillen MJ, Moreto J, Sara P, Martinez-Iniesta M, Figueras A, Padulles L, Garcia-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Marti L, Ponce J, Mollevi DG, Capella G, Condom E, Vinals F, Huertas D, Cuevas C, Esteller M, Aviles P, Villanueva A. Clin Cancer Res. 2012 Aug 15. [Epub ahead of print]
Raül Toran | EurekAlert!
Closing the carbon loop
08.12.2016 | University of Pittsburgh
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences